http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3342865-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6292754ba3382a49ad6bedab17e172a9
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-14134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-14122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10062
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10041
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-40
filingDate 2016-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_884369a03d02e1eda9677146c8e27b3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a34d04fe5d247dcbfea77bf5057183c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73cd22c5c019da0ee32128effd90eeb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b578f825cd793fa7a5ac5ff2300ffb28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3423eb3189a7efc4be0ce495b0a999f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b17763aa33a730ea918e5ae95d45671c
publicationDate 2018-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3342865-A1
titleOfInvention Ebola virus disease vaccine taking human replication deficient adenovirus as vector
abstract Provided are an Ebola virus envelope glycoprotein (that is GP protein) codon optimized nucleotide sequence, a human replication deficient recombinant adenovirus capable of expressing the nucleotide sequence, and applications in preparing a vaccine for preventing Ebola virus diseases. The nucleotide sequence takes a replication deficient 5 type adenovirus that is lack of E1 and E3 in a combined mode as a vector, HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and carried protective antigenic genes are codon optimized Zaire type Ebola virus Makona strain envelope glycoprotein genes. After the envelope glycoprotein genes are optimized by codon, the expression level in transfection cells is obviously improved.
priorityDate 2016-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6235
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID442070
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405470
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399539
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644209
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409332
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8272
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409975

Total number of triples: 40.